ProKidney Corp (PROK)
Market Open
11 Sep, 15:11
NASDAQ (CM) NASDAQ (CM) Primary $
1. 83
-0.01
-0.2717%
$
645.61M Market Cap
- P/E Ratio
- Div Yield
266,921 Volume
-1.22 Eps
$ 1.84
Previous Close 
Want to track PROK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks | 1 year ago
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that's suitable for the FDA.
Seekingalpha | 1 year ago
